Law spurs regulators to heed patients’ priorities
July 10, 2012
When the prescription weight-loss drug Belviq (lorcaserin) was approved on 27Â June, onlookers wondered what had changed. Two years ago, the US Food and Drug Administration (FDA) rejected the drug because of the possibility that it can damage heart valves, like similar anti-obesity drugs. (Nature News)
